We have previously demonstrated that high serum A‐FABP levels are independently associated with diabetic nephropathy and diabetic macrovascular diseases,37 and a recent study showed that serum A‐FABP predicts CV events in end‐stage renal disease.38 Furthermore, Tuncman et al39 demonstrated that the presence of a genetic variant at the A‐FABP promoter region that results in decreased A‐FABP expression was associated with reduced risk for CVD. Here, FABP4 is linked to diabetic kidney disease.